Expression and methylation status of vascular endothelial growth factor and thrombospondin-1 genes in congenital factor XIII-deficient patients with intracranial hemorrhage.
Journal
Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551
Informations de publication
Date de publication:
01 Jul 2021
01 Jul 2021
Historique:
pubmed:
9
6
2021
medline:
15
7
2021
entrez:
8
6
2021
Statut:
ppublish
Résumé
Congenital factor XIII (FXIII) deficiency is one of the rarest bleeding disorders, with an incidence of one per 2 million persons. Intracranial hemorrhage (ICH), a major cause of mortality in FXIII deficiency, is reported to be associated with vascular endothelial growth factor (VEGF) and thrombospondin-1 (TSP-1). Therefore, we investigated the association of VEGF and TSP-1 expression and methylation patterns with ICH in congenital FXIII deficiency patients. This study was conducted on 40 participants with FXIII, 20 of whom experienced ICH (cases), and 20 who did not (controls). Methylation pattern, gene expression, and plasma protein level were assessed using bisulfite sequencing PCR, quantitative real-time PCR, and ELISA. We found a partially methylated pattern for both VEGF and TSP-1 (P > 0.05). VEGF mRNA levels of the case group were significantly higher than those of the control group (P < 0.05), whereas TSP-1 mRNA levels did not show significant upregulation (P > 0.05). Plasma VEGF and TSP-1 concentrations in the case group were higher, but not statistically significant (P > 0.05). Our findings showed no obvious correlation between VEGF or TSP-1 methylation patterns and expression, suggesting that their expression in FXIII deficiency may not solely be controlled by gene methylation.
Identifiants
pubmed: 34102652
doi: 10.1097/MBC.0000000000001039
pii: 00001721-202107000-00003
doi:
Substances chimiques
Thrombospondin 1
0
Vascular Endothelial Growth Factor A
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
317-322Informations de copyright
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Références
Dorgalaleh A, Rashidpanah J. Blood coagulation factor XIII and factor XIII deficiency. Blood Rev 2016; 30:461–475.
Shi DY, Wang SJ. Advances of coagulation factor XIII. Chin Med J (Engl) 2017; 130:219–223.
Dorgalaleh A, Assadollahi V, Tabibian S, Shamsizadeh M. Molecular basis of congenital factor XIII deficiency in Iran. Clin Appl Thromb Hemost 2018; 24:210–216.
Alavi SER, Jalalvand M, Assadollahi V, Tabibian S, Dorgalaleh A. Intracranial hemorrhage: a devastating outcome of congenital bleeding disorders – prevalence, diagnosis, and management, with a special focus on congenital factor XIII deficiency. Semin Thromb Hemost 2018; 44:267–275.
Dorgalaleh A, Kazemi A, Zaker F, Shamsizadeh M, Rashidpanah J, Mollaei M. Laboratory diagnosis of factor XIII deficiency, routine coagulation tests with quantitative and qualitative methods. Clin Lab 2016; 62:491–498.
Tang T, Liu XJ, Zhang ZQ, Zhou HJ, Luo JK, Huang JF, et al. Cerebral angiogenesis after collagenase-induced intracerebral hemorrhage in rats. Brain Res 2007; 1175:134–142.
Lee HJ, Kim KS, Park IH, Kim SU. Human neural stem cells over-expressing VEGF provide neuroprotection, angiogenesis and functional recovery in mouse stroke model. PLoS One 2007; 2:e156.
Sun Y, Jin K, Xie L, Childs J, Mao XO, Logvinova A, et al. VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 2003; 111:1843–1851.
Zhang ZG, Zhang L, Jiang Q, Zhang R, Davies K, Powers C, et al. VEGF enhances angiogenesis and promotes blood–brain barrier leakage in the ischemic brain. J Clin Invest 2000; 106:829–838.
Josko J. Cerebral angiogenesis and expression of VEGF after subarachnoid hemorrhage (SAH) in rats. Brain Res 2003; 981:58–69.
Rosenstein JM, Krum JM, Ruhrberg C. VEGF in the nervous system. Organogenesis 2010; 6:107–114.
Zachary I. Neuroprotective role of vascular endothelial growth factor: signalling mechanisms, biological function, and therapeutic potential. Neurosignals 2005; 14:207–221.
Namiecińska M, Marciniak K, Nowak JZ. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig Med Dosw 2005; 59:573–583.
Shen YF, Wang WH, Yu WH, Dong XQ, Du Q, Yang DB, et al. The prognostic value of plasma thrombospondin-1 concentrations after aneurysmal subarachnoid hemorrhage. Clinica Chimica Acta 2015; 448:155–160.
Yamauchi M, Imajoh-Ohmi S, Shibuya M. Novel antiangiogenic pathway of thrombospondin-1 mediated by suppression of the cell cycle. Cancer Sci 2007; 98:1491–1497.
Gao JB, Tang WD, Wang HX, Xu Y. Predictive value of thrombospondin-1 for outcomes in patients with acute ischemic stroke. Clinica Chimica Acta 2015; 450:176–180.
Dardik R, Solomon A, Loscalzo J, Eskaraev R, Bialik A, Goldberg I, et al. Novel proangiogenic effect of factor XIII associated with suppression of thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003; 23:1472–1477.
Dardik R, Loscalzo J, Inbal A. Factor XIII (FXIII) and angiogenesis. J Thromb Haemost 2006; 4:19–25.
Yang AL, Zhou HJ, Lin Y, Luo JK. Thrombin promotes the expression of thrombospondin-1 and -2 in a rat model of intracerebral hemorrhage. J Neurol Sci 2012; 323:141–146.
Zhou HJ, Zhang HN, Tang T, ZHong JH, Qi Y, Luo JK, et al. Alteration of thrombospondin-1 and -2 in rat brains following experimental intracerebral hemorrhage. J Neurosurg 2010; 113:820–825.
Noroozi-Aghideh A, Kashani khatib Z, Naderi M, Dorgalaleh A, Yaghmaie M, Paryan M, Alizadeh S. Expression and CpG island methylation pattern of MMP-2 and MMP-9 genes in patients with congenital factor XIII deficiency and intracranial hemorrhage. Hematology 2019; 24:601–605.
Jung S, Moon KS, Jung TY, Kim IY, Lee YH, Rhu HH, et al. Possible pathophysiological role of vascular endothelial growth factor (VEGF) and matrix metalloproteinases (MMPs) in metastatic brain tumor-associated intracerebral hemorrhage. J Neurooncol 2006; 76:257–263.
Cheng SY, Nagane M, Huang HS, Cavenee WK. Intracerebral tumor-associated hemorrhage caused by overexpression of the vascular endothelial growth factor isoforms VEGF121 and VEGF165 but not VEGF189. Proc Natl Acad Sci U S A 1997; 94:12081–12087.
Zheng J, Sun J, Yang L, Zhao B, Fan Z. The potential role of vascular endothelial growth factor as a new biomarker in severe intracerebral hemorrhage. J Clin Lab Anal 2017; 31:e22076.
Shaligram SS, Winkler E, Cooke D, Su H. Risk factors for hemorrhage of brain arteriovenous malformation. CNS Neurosci Ther 2019; 25:1085–1095.
Bernstein JE, Savla P, Dong F, Zampella B, Wiginton JG, Miulli DE, et al. Inflammatory markers and severity of intracerebral hemorrhage. Cureus 2018; 10:e3529.
Wicinski M, Al Drawi AS, Malinowski B, Stolarek W. Evaluation of vascular endothelial growth factor A and selected parameters of coagulation and fibrinolysis in a group of patients with subarachnoid haemorrhage. Biomed Res Int 2019; 2019:
Lee CZ, Xue Z, Zhu Y, Yang GY, Young WL. Matrix metalloproteinase-9 inhibition attenuates vascular endothelial growth factor-induced intracerebral hemorrhage. Stroke 2007; 38:2563–2568.
Sobrino T, Arias S, Rodríguez-González R, Brea D, Silva Y, de la Ossa NP, et al. High serum levels of growth factors are associated with good outcome in intracerebral hemorrhage. J Cereb Blood Flow Metab 2009; 29:1968–1974.
Poon RT, Chung KK, Cheung ST, Lau CP, Tong SW, Leung KL, et al. Clinical significance of thrombospondin 1 expression in hepatocellular carcinoma. Clin Cancer Res 2004; 10:4150–4157.
Esemuede N, Lee T, Pierre-Paul D, Sumpio BE, Gahtan V. The role of thrombospondin-1 in human disease. J Surg Res 2004; 122:135–142.